尿酸：帕金森病风险、诊断和预后的新型生物标志物。
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
机构信息
Massachusetts General Hospital, 114 16th Street, Boston, MA 02129, USA.
出版信息
Biomark Med. 2010 Oct;4(5):701-12. doi: 10.2217/bmm.10.94.
Abstract
A growing number of studies have correlated higher urate levels with a lower risk of developing Parkinson's disease (PD) and with a favorable rate of disease progression, indicating that urate could be an important biomarker of the pathophysiology underlying PD. Dietary and genetic determinants of urate have also been linked to a reduced risk or delayed onset of PD. Based on the known antioxidant and metal complexing properties of urate, together with evidence for oxidative stress as a contributor to neurodegeneration in PD, urate may serve as an endogenous neuroprotectant that helps reduce the risk and rate of the disease. In this article we review the convergent biological, epidemiological and clinical data that identify urate as a promising biomarker of the risk, diagnosis and prognosis of PD.
摘要
越来越多的研究表明，尿酸水平与帕金森病（PD）的发病风险降低和疾病进展有利相关，这表明尿酸可能是 PD 潜在病理生理学的重要生物标志物。尿酸的饮食和遗传决定因素也与 PD 的风险降低或发病延迟有关。基于尿酸已知的抗氧化和金属络合特性，以及氧化应激是 PD 神经退行性变的一个促成因素的证据，尿酸可能作为一种内源性神经保护剂，有助于降低 PD 的发病风险和速度。在本文中，我们回顾了将尿酸确定为 PD 的风险、诊断和预后有希望的生物标志物的收敛性生物学、流行病学和临床数据。
相似文献
1
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
Biomark Med. 2010 Oct;4(5):701-12. doi: 10.2217/bmm.10.94.
2
Urate as a Marker of Risk and Progression of Neurodegenerative Disease.
Neurotherapeutics. 2017 Jan;14(1):148-153. doi: 10.1007/s13311-016-0497-4.
3
Targeting urate to reduce oxidative stress in Parkinson disease.
Exp Neurol. 2017 Dec;298(Pt B):210-224. doi: 10.1016/j.expneurol.2017.06.017. Epub 2017 Jun 13.
4
Urate in Parkinson's disease: more than a biomarker?
Curr Neurol Neurosci Rep. 2012 Aug;12(4):367-75. doi: 10.1007/s11910-012-0282-7.
5
Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):300-5. doi: 10.1073/pnas.1217296110. Epub 2012 Dec 17.
6
Urate as a marker of development and progression in Parkinson's disease.
Drugs Today (Barc). 2011 May;47(5):369-80. doi: 10.1358/dot.2011.47.5.1591834.
7
Gout, hyperuricemia, and Parkinson's disease: a protective effect?
Curr Rheumatol Rep. 2010 Apr;12(2):149-55. doi: 10.1007/s11926-010-0083-4.
8
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.
9
Urate as a predictor of the rate of clinical decline in Parkinson disease.
Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247.
10
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14351-6. doi: 10.1073/pnas.1001072107. Epub 2010 Jul 26.
引用本文的文献
1
Classification of Parkinson's disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome.
NPJ Parkinsons Dis. 2025 Jul 15;11(1):202. doi: 10.1038/s41531-025-01026-8.
2
The impact of uric acid levels in the pathophysiology and its contribution to the prediction of diagnosis in restless legs syndrome.
Sleep Biol Rhythms. 2024 Aug 22;23(1):39-45. doi: 10.1007/s41105-024-00549-6. eCollection 2025 Jan.
3
Hyperuricemia and the small intestine: Transport mechanisms and co-morbidities.
Biotechnol Notes. 2022 May 25;3:32-37. doi: 10.1016/j.biotno.2022.05.001. eCollection 2022.
4
Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.
CNS Neurol Disord Drug Targets. 2024;23(8):996-1014. doi: 10.2174/0118715273258646230920074421.
5
Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies.
Int J Mol Sci. 2023 Jan 2;24(1):789. doi: 10.3390/ijms24010789.
6
Parkinson's Disease and the Gut Microbiome in Rural California.
J Parkinsons Dis. 2022;12(8):2441-2452. doi: 10.3233/JPD-223500.
7
Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review.
Biomedicines. 2022 Mar 11;10(3):653. doi: 10.3390/biomedicines10030653.
8
Plasma Metabolite Signature Classifies Male LRRK2 Parkinson's Disease Patients.
Metabolites. 2022 Feb 5;12(2):149. doi: 10.3390/metabo12020149.
9
Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?
Front Neurosci. 2021 Aug 24;15:703783. doi: 10.3389/fnins.2021.703783. eCollection 2021.
10
Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.
Mol Neurobiol. 2021 Nov;58(11):5517-5532. doi: 10.1007/s12035-021-02500-z. Epub 2021 Aug 5.
本文引用的文献
1
Plasma urate and Parkinson's disease in women.
Am J Epidemiol. 2010 Sep 15;172(6):666-70. doi: 10.1093/aje/kwq195. Epub 2010 Aug 2.
2
Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease.
J Mol Neurosci. 2011 Mar;43(3):246-50. doi: 10.1007/s12031-010-9409-y. Epub 2010 Jun 30.
3
Uric acid transport and disease.
J Clin Invest. 2010 Jun;120(6):1791-9. doi: 10.1172/JCI42344. Epub 2010 Jun 1.
4
Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey.
Mov Disord. 2010 May 15;25(7):932-6. doi: 10.1002/mds.23070.
5
The relationship between uric acid levels and Huntington's disease progression.
Mov Disord. 2010 Jan 30;25(2):224-8. doi: 10.1002/mds.22907.
6
Uric acid as a CNS antioxidant.
J Alzheimers Dis. 2010;19(4):1331-6. doi: 10.3233/JAD-2010-1330.
7
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease.
Cardiovasc Psychiatry Neurol. 2009;2009:282059. doi: 10.1155/2009/282059. Epub 2009 Nov 4.
8
[Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease].
Zhonghua Yi Xue Za Zhi. 2009 Jun 16;89(23):1633-5.
9
Urate as a predictor of the rate of clinical decline in Parkinson disease.
Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247.
10
Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
Clin Neurol Neurosurg. 2009 Nov;111(9):724-8. doi: 10.1016/j.clineuro.2009.06.012. Epub 2009 Jul 24.
Zotero 插件